Incyte Buys Vega Therapeutics for Up to $2 Billion to Bring New Once-a-Month Shot for Bleeding Disorder
Incyte is buying Vega Therapeutics to add VGA039 — a new once-monthly under-the-skin injection for von Willebrand disease (VWD).
/ 352 items
#XY Event-Driven Stocks↓
Cullinan’s CLN-978 Shows Deep B-Cell Depletion and Remissions in Lupus and RA
Cullinan Therapeutics’ CLN-978 T-cell engager showed deep B-cell depletion and clinical remissions in hard-to-treat lupus and rheumatoid arthritis patients after a single dose at EULAR 2026.
Eli Lilly Stock Surges as Retatrutide Delivers 28% Weight Loss and Major Relief for Sleep Apnea & Knee Pain
Lilly stock jumps as new obesity drug helps people lose ~30% body weight and improve health, showing strong promise for future treatment.
FDA Gives Green Light to CardiAMP Heart Cell Therapy for Heart Failure
FDA confirms BioCardia’s CardiAMP Heart Failure II trial may support Premarket Approval for ischemic heart failure.
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.